Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015;16(2):204-6.
doi: 10.1080/15384047.2014.1002369.

Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma

Tracy C Okoli  1 , Cody J Peer, Kieron Dunleavy, William D Figg
Affiliations
Comment

Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma

Tracy C Okoli et al. Cancer Biol Ther. 2015.

Abstract

Indolent Non-Hodgkin Lymphomas (iNHL) are typically B-cell malignancies and are incurable with current standard approaches. Thus, there is a demand for novel agents specific for this group of disorders. In a phase II study published by Gopal et al. in the New England Journal of Medicine, idelalisib, a small molecule inhibitor of PI3Kδ that was FDA approved in July of 2014, was shown to be effective when combined with rituximab in patients who cannot tolerate chemotherapy and as last line therapy in patients with iNHL refractory to 2 prior systemic therapies. Idelalisib demonstrated tolerable diarrhea, fatigue, nausea, pyrexia, and cough. While this novel agent is a clinically significant addition to the iNHL arsenal, further research is needed to determine its most appropriate place in iNHL therapy.

Keywords: B-cell chronic lymphocytic leukemia; Furman et al; Gopal et al; PI3Kδ Inhibition; follicular lymphoma; idelalisb; indolent Non-Hogkin Lymphoma; rituximab; small lymphocytic lymphoma; targeted therapy.

PubMed Disclaimer

Comment on

  • PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
    Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. Gopal AK, et al. N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22. N Engl J Med. 2014. PMID: 24450858 Free PMC article. Clinical Trial.

Similar articles

See all similar articles

References

    1. American Cancer Society Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
    1. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Chapter 109. Lymphomas. In: Pharmacotherapy: A Pathophysiologic Approach, 9e. New York, NY: The McGraw-Hill Companies; 2014. Available at: http://mhmedical.com/content.aspx?aid=57513076.
    1. Rituximab In: Micromedex 2.0 [online database]. Greenwood Village: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed August 08, 2014.
    1. Kocs D, Fendrick A. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 2003; 9(5):393-400; quiz 401-402; PMID:12744301 - PubMed
    1. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, et al. . PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370(11):1008-18; PMID:24450858; http://dx.doi.org/10.1056/NEJMoa1314583 - DOI - PMC - PubMed

LinkOut - more resources